Trichostatin A (TSA), as a class I and class II HDAC inhibitor, has been studied in other pathological contexts, with promising results in the treatment of Alzheimer’s disease [29], cancer [30], or as a potential radiomitigator [31]. Here, HDAC9 is linked to early-onset autosomal dominant Alzheimer disease.